MODERNA : to start their final stage clinical trials of its vaccine against COVID-19

Phase-III study of 30,000 subjects expected to begin in July,2020 at 100μg dose level.

Vaccine candidate – mRNA-1273

         A clinical stage biotechnology company pioneering mRNA therapeutics and vaccines to create a new generation of transformative medicine for patients, announced progress on late-stage development of mRNA-1273.

With the phase-III dose being finalized at 100μg, the company remains on track to be able to deliver approximately 500 million doses per year.

About mRNA-1273 »

          It is an mRNA vaccine against COVID-19 encoding for a perfusion stabilized form of the Spike(S) protein.

First clinical batch (Phase-I)  – March 16,2020

By SUBHAM SINGHA (Science & Tech Division)

IGNITED MINDS

Click here to follow us on YouTube

Click here to follow us on Facebook


Comments

Popular posts from this blog

Shailene Woodley and Ansel Elgort are excited for Sushant's Dil Bechara

IIT-Gandhinagar team develops AI-based tool to detect COVID-19 using chest X-rays

10 Indian Web series You Shouldn't Miss